China finally has a verdict on the husband-wife investigator team linked to GlaxoSmithKline's bribery scandal: U.K. citizen Peter Humphrey is headed for 2.5 years behind bars, and his American wife, Yu Yingzeng, will get 2 years, Pharmafile reports.
General Electric's $2 billion commitment to invest in Africa includes the launch of a program to train biomedical engineering technicians in Nigeria, where patients are dying of treatable conditions because the devices to treat them are left unfixed due to a lack of know-how, according to a prominent nongovernmental organization.
Quintiles has signed a deal with a Roche diagnostics subsidiary to offer cancer screenings in China, looking to capitalize on the growing market for clinical trials in the country.
The $84,000 U.S. treatment price that Gilead Sciences is charging for its hepatitis C drug Sovaldi has elicited pleas from politicians and threats from payers, who say the U.S. healthcare system cannot bear the cost. But in India, Gilead will offer it at a discount--a 99% discount.
To aid it with marketing its oncology lineup in India, the French drugmaker has brought on local company Emcure Pharmaceuticals, PMLiVE reports.
General Electric is launching healthcare initiatives in Africa in partnership with governments and a $20 million commitment from the GE Foundation to improve the continent's healthcare. Most notably, the GE Foundation is funding a $1.5 million biomedical training program in Nigeria to ensure that the country has technicians who can fix devices ranging from blood pressure cuffs to X-rays.
On Friday, 19-year-old Harvey Humphrey visited his parents, the husband-and-wife team of private detectives who did investigative work for GlaxoSmithKline's disgraced China office, for the first time since they were detained by Chinese police last summer. The family saga painfully illustrates the potential pitfalls of doing business in China.
Sanofi's in line to rack up blockbuster sales after hitting a wide-open market with its dengue vaccine, analysts predict. And company CEO Chris Viehbacher thinks those sales could start rolling in before next year is out.
The chilly sales climate in China is just now warming up after last summer's wave of bribery accusations spooked doctors and sales reps. But as far as Merck KGaA is concerned, China is warm enough to deliver doubled revenues in the region. And that's exactly what the German drugmaker's shooting for.
Indian CRO GVK Biosciences has spent the last year transitioning from a discovery-focused contractor to a full-service developer, now launching a dedicated clinical research unit to reach drugmakers around the world.